Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Moving Toward PAT Standardized Nomenclature And Definitions

This article was originally published in The Pink Sheet Daily

Executive Summary

The process analytical technology component of FDA's drug quality initiative will be assisted by an independent standards-making effort and agency encouragement of comparability protocols. Part 11 and dispute resolution are other quality initiative components drawing industry input.

You may also be interested in...



FDA Expects 25 Formal Dispute Resolution Requests Annually On GMP Issues

The agency has not changed its projection that the number of annual requests for formal dispute resolution will reach 25, almost double the current number of informal disputes, despite the results of a year-long pilot program that had little industry participation.

FDA Expects 25 Formal Dispute Resolution Requests Annually On GMP Issues

The agency has not changed its projection that the number of annual requests for formal dispute resolution will reach 25, almost double the current number of informal disputes, despite the results of a year-long pilot program that had little industry participation.

Rapid Microbiology Methods Submissions Reviewed By Special FDA Team

The agency’s four-person rapid microbiology methods review and inspection team was formed under the process analytical technology initiative. FDA is “very enthusiastic” about methods that allow for faster microbial testing.

Topics

UsernamePublicRestriction

Register

LL1133546

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel